
Loehmann's department store gets new life after closing doors 11 years ago
A pop-up version of the century-old department store, which went bankrupt in 2013, will open Aug. 21 on Long Island, its new owner said.
Rival discounter Century 21 quietly acquired the brand in 2020, as The Post reported, and is relaunching it in a series of pop-up stores, starting at the Tanger Outlets at Deer Park.
Advertisement
3 Loehmann's closed its doors seemingly for forever in 2014.
Penske Media via Getty Images
The initial two-week warehouse sale will also include Loehmann's famous 'Back Room,' which in its heyday featured deeply marked-down luxury brands from Michael Kors, Calvin Klein, Ralph Lauren, Fendi, Oscar de la Renta, Marc Jacobs among others.
'The hope is that 11 years later that there is some nostalgia for the brand and people fondly look back,' Larry Mentzer, Century 21's chief operating officer, said in an exclusive interview with The Post.
Mentzer declined to divulge which brands will be available in the Back Room, as most designers don't want to be associated with discounting.
Advertisement
There will be a mix of 'well-known European designer labels, household names and emerging brands,' he said.
Another pop-up is planned for Florida this year and one is coming to the Big Apple next year, Mentzer said.
'We think there is real value in the brand going forward,' Mentzer said, adding, 'off-price is the hottest sector in retail right now.'
Advertisement
3 At its peak, Loehmann's operated some 100 stores in the 1990s.
Astrid Stawiarz/NY Post
The Gindi family, which owns Century 21, scooped up the Loehmann's brand for about $300,000 after the chain was liquidated following its third bankruptcy filing, sources told The Post.
The New York-based company, which itself filed for bankruptcy in 2020 before reemering in 2022, is one of the last discount department stores that focuses on designer labels.
It has oulasted Filine's Basement, Daffy's and Syms, which all shuttered more than a decade ago, squeezed out by larger, better funded competitors like TJ Maxx and Ross Stores.
Advertisement
3 Century 21 acquired Loehmann's in 2000 for about $300,000, according to a source.
Robert Miller
At its peak, Loehmann's operated about 100 stores across the country in the 1990s, while Century 21 had 13 stores mostly in the New York metro area.
Now, it operates just one at its flagship location in lower Manhattan.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
27 minutes ago
- Yahoo
Broadridge Financial beats quarterly profit view on robust demand for mainstay businesses
(Reuters) -Fintech firm Broadridge Financial reported fourth-quarter profit above Wall Street estimates on Tuesday, helped by demand for its investor communication offerings and global technology businesses. WHY IT'S IMPORTANT Broadridge is one of the largest investor communication and technology services provider in the U.S. to banks, broker-dealers, and other financial institutions. It plays a critical role in enabling proxy voting, trade processing, and regulatory compliance. The company's two mainstay businesses are investor communication solutions, which account for the majority of its revenue, and global technology and operations. Investor communication solutions engage in distribution of proxy materials and other corporate communication. The global technology and operations unit offers products such as desktop productivity tools, portfolio management, cash management, clearance and settlement. CONTEXT The Lake Success, New York-based company, benefited from steady demand for proxy communications from companies to shareholders ahead of annual meetings. It has also been increasingly leaning on growth in its digital wealth and market infrastructure platforms, as volatile markets and revived deal activity boost client need for real-time data and analytics. KEY QUOTE "We are on track to deliver again on our three-year top- and bottom-line growth objectives," said CEO Tim Gokey. Broadridge targets 7–9% recurring revenue CAGR and 8–12% adjusted EPS CAGR over fiscal years 2024 to 2026. BY THE NUMBERS Broadridge posted adjusted earnings per share of $3.55 for the three months ended June 30, compared with analysts' average estimate of $3.50, according to data compiled by LSEG. Revenue at its investor communication solutions unit grew 5% to $1.60 billion. The global technology and operations segment also saw a 12% revenue jump to $464.7 million. The company announced fiscal 2026 guidance of 5-7% recurring revenue growth constant currency and 8-12% adjusted EPS growth. Total revenue for the quarter increased 6% to $2.07 billion. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Lucid Diagnostics to Participate in Upcoming Investor Conferences
NEW YORK, Aug. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that management will participate in the following upcoming investor conferences: 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference 1x1 Meetings: August 11-12, 2025 Location: Virtual Canaccord Genuity 45th Annual Growth Conference Fireside Chat: August 13, 2025, at 2:30 PM ET Location: Boston, MA The live and archived webcast of the Canaccord Genuity fireside chat can be accessed by clicking here or by visiting the Investor Relations Section of the Lucid Diagnostics website. A replay of the webcast will be available on the website for 30 days following the conclusion of the live broadcast. About Lucid DiagnosticsLucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients. For more information, please visit and for more information about its parent company PAVmed, please visit View original content to download multimedia: SOURCE Lucid Diagnostics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
If You'd Invested $1,000 in PFE 5 Years Ago, Here's How Much You'd Have Today
Key Points Pfizer's stock is down over 60% from its December 2021 peak (as of Aug. 1). A drop in COVID-19 vaccines and treatment has caused a drop in Pfizer's revenue. Pfizer's stock appears to be in bargain territory for long-term investors. 10 stocks we like better than Pfizer › Five years ago, the world was in the thick of the COVID-19 global pandemic, bringing Pfizer (NYSE: PFE) into the spotlight because of the role it played in developing the COVID-19 vaccine with its partner BioNTech. It was able to get U.S. Food and Drug Administration (FDA) approval for its COVID-19 vaccine on Dec. 11, 2020, and it was released on Dec. 14, 2020. From mid-2020 to late 2021, Pfizer's stock skyrocketed, but since hitting its peak, it has reversed course. Had you invested $1,000 into Pfizer's stock on Aug. 1, 2020, your investment would only be worth around $638 as of Aug. 1, 2025. Pfizer's dividend would've cushioned some of the blow, but an investment then would still be less than your initial investment, at $828. Why has Pfizer's stock struggled the past few years? Much of Pfizer's stock price troubles since hitting its Dec. 21 peak come down to a decline in demand for its COVID-19 vaccine and treatments, anticipated patent expirations on drugs like Ibrance (breast cancer) and Eliquis (blood clots), and an underwhelming pipeline. All isn't lost with Pfizer's stock, however. At its current levels -- trading at 7.7 times forward earnings -- Pfizer seems to be flirting with bargain territory. I don't expect a quick turnaround, but this low valuation gives it more long-term upside than downside. It also helps that the stock's dividend yield sits above 7.3%, more than 5.5 times the S&P 500 average. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Stefon Walters has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends BioNTech Se. The Motley Fool has a disclosure policy. If You'd Invested $1,000 in PFE 5 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool Sign in to access your portfolio